Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak - Journal of clinical oncology, 2002 - ascopubs.org
Vascular endothelial growth factor A (VEGF-A), the founding member of the vascular
permeability factor (VPF)/VEGF family of proteins, is an important angiogenic cytokine with …
permeability factor (VPF)/VEGF family of proteins, is an important angiogenic cytokine with …
Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer
L Rydzewska, J Tierney, CL Vale… - Cochrane Database of …, 2012 - cochranelibrary.com
Background A previous systematic review found that giving neoadjuvant chemotherapy
before surgery improved survival compared with radiotherapy. However, the role of …
before surgery improved survival compared with radiotherapy. However, the role of …
Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers
LS Rosen - Cancer control, 2002 - journals.sagepub.com
Angiogenesis is required for tumor growth and metastasis and, therefore, represents an
exciting target for cancer treatment. Angiogenesis is a complex process that is tightly …
exciting target for cancer treatment. Angiogenesis is a complex process that is tightly …
Radiotherapy resistance: identifying universal biomarkers for various human cancers
I Larionova, M Rakina, E Ivanyuk, Y Trushchuk… - Journal of cancer …, 2022 - Springer
Radiotherapy (RT) is considered as a standard in the treatment of most solid cancers,
including glioblastoma, lung, breast, rectal, prostate, colorectal, cervical, esophageal, and …
including glioblastoma, lung, breast, rectal, prostate, colorectal, cervical, esophageal, and …
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled …
RP Symonds, C Gourley, S Davidson, K Carty… - The Lancet …, 2015 - thelancet.com
Background Patients treated with standard chemotherapy for metastatic or relapsed cervical
cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of …
cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of …
RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical …
T Schefter, K Winter, JS Kwon, K Stuhr, K Balaraj… - International Journal of …, 2014 - Elsevier
Purpose Radiation Therapy Oncology Group 0417 was a phase II study that explored the
safety and efficacy of the addition of bevacizumab to chemoradiation therapy. The safety …
safety and efficacy of the addition of bevacizumab to chemoradiation therapy. The safety …
Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer
JD Carpini, AK Karam, L Montgomery - Angiogenesis, 2010 - Springer
Tumor neovascularization is a complex process that plays a crucial role in the development
of many different types of cancer. Vascular endothelial growth factor (VEGF) is a potent …
of many different types of cancer. Vascular endothelial growth factor (VEGF) is a potent …
Phase I study of bevacizumab added to fluorouracil-and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer
TY Seiwert, DJ Haraf, EEW Cohen… - Journal of Clinical …, 2008 - ascopubs.org
Purpose We conducted a phase I dose escalation study to determine the maximum-tolerated
dose (MTD) and dose-limiting toxicity (DLT) of bevacizumab, when added to the standard …
dose (MTD) and dose-limiting toxicity (DLT) of bevacizumab, when added to the standard …
Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?
R Cooper, S Sarioğlu, S Sökmen, M Füzün… - British journal of …, 2003 - nature.com
The aim of the study is to evaluate the pattern and level of expression of glucose transporter-
1 (GLUT-1) in rectal carcinoma in relation to outcome as a potential surrogate marker of …
1 (GLUT-1) in rectal carcinoma in relation to outcome as a potential surrogate marker of …
Carcinoma and other tumors of the cervix
TC Wright, A Ferenczy, RJ Kurman - … pathology of the female genital tract, 1994 - Springer
The World Health Organization (WHO) classification for tumors of the cervix has been
revised recently in collaboration with the International Society of GynecolOgical …
revised recently in collaboration with the International Society of GynecolOgical …